A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
The use of adoptive cell therapy for the treatment of SARS-CoV-2 in a patient after allogeneic hematopoietic stem cell transplantation
2022
Voprosy gematologii/onkologii i immunopatologii v pediatrii
The COVID-19 pandemic continues to be a major public health threat worldwide. The course of this disease in immunocompromised patients is significantly different from that in healthy subjects, which is associated with the impossibility of virus elimination through their own adaptive immune response. Delayed immune reconstitution after hematopoietic stem cell transplantation (which may take months after the procedure) increases the risk of life-threatening COVID-19 infection necessitating a
doi:10.24287/1726-1708-2022-21-2-112-117
fatcat:sm4mxs3vfnaxla5gxscm4kwplu